Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report.
Federica CalòLorenzo OnoratoMariantonietta PisaturoAntonio PintoLoredana AlessioCaterina MonariCarmine MinichiniManuela ArcamoneAlessandra Di FraiaLuigi AtripaldiClaudia TiberioNicola CoppolaPublished in: Vaccines (2022)
Few data are available regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. Vaccination may have a suboptimal efficacy in this population, in particular if patients are exposed to anti-B-cell therapy. We report the virological and clinical characteristics of a patient with follicle center lymphoma under bimonthly maintenance therapy with obinutuzumab, an anti-CD20 monoclonal antibody. Despite three doses of BNT162b2 vaccine, the patient was infected by the SARS-CoV-2 Omicron variant. After an initial period of clinical and molecular remission due to early therapy with sotrovimab, the patient experienced a fatal relapse sustained by the same viral strain.
Keyphrases
- sars cov
- monoclonal antibody
- cell therapy
- case report
- end stage renal disease
- newly diagnosed
- ejection fraction
- stem cells
- respiratory syndrome coronavirus
- chronic kidney disease
- systematic review
- randomized controlled trial
- coronavirus disease
- prognostic factors
- diffuse large b cell lymphoma
- machine learning
- patient reported outcomes
- hiv infected
- intensive care unit
- big data
- patient reported
- deep learning
- antiretroviral therapy
- artificial intelligence
- bone marrow